# CiPA Phase 1 ECG Biomarker Validation Study

> **NCT03070470** · PHASE1 · COMPLETED · sponsor: **Food and Drug Administration (FDA)** · enrollment: 60 (actual)

## Conditions studied

- Drug-induced QT Prolongation
- Pharmacokinetics
- Pharmacodynamics

## Interventions

- **DRUG:** Ranolazine
- **DRUG:** Verapamil
- **DRUG:** Lopinavir / Ritonavir
- **DRUG:** Chloroquine
- **DRUG:** Placebo
- **DRUG:** Dofetilide and Diltiazem

## Key facts

- **NCT ID:** NCT03070470
- **Lead sponsor:** Food and Drug Administration (FDA)
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-14
- **Primary completion:** 2017-06-26
- **Final completion:** 2017-06-26
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03070470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03070470, "CiPA Phase 1 ECG Biomarker Validation Study". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03070470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*